HRP20000002B1 - Azetidinylpropylpiperidine derivatives, intermediates and use as tachykinin antagonists - Google Patents

Azetidinylpropylpiperidine derivatives, intermediates and use as tachykinin antagonists

Info

Publication number
HRP20000002B1
HRP20000002B1 HR970497A HRP20000002A HRP20000002B1 HR P20000002 B1 HRP20000002 B1 HR P20000002B1 HR 970497 A HR970497 A HR 970497A HR P20000002 A HRP20000002 A HR P20000002A HR P20000002 B1 HRP20000002 B1 HR P20000002B1
Authority
HR
Croatia
Prior art keywords
intermediates
tachykinin antagonists
azetidinylpropylpiperidine
derivatives
azetidinylpropylpiperidine derivatives
Prior art date
Application number
HR970497A
Other languages
English (en)
Inventor
David Alker
Thomas Victor Magee
Graham Nigel Maw
Donald Stuart Middleton
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HRP20000002A2 publication Critical patent/HRP20000002A2/hr
Publication of HRP20000002B1 publication Critical patent/HRP20000002B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR970497A 1997-07-04 2000-01-04 Azetidinylpropylpiperidine derivatives, intermediates and use as tachykinin antagonists HRP20000002B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9714129.5A GB9714129D0 (en) 1997-07-04 1997-07-04 Azetidines
PCT/EP1998/004177 WO1999001451A1 (en) 1997-07-04 1998-07-01 Azetidinylpropylpiperidine derivatives, intermediates and use as tachykinin antagonists

Publications (2)

Publication Number Publication Date
HRP20000002A2 HRP20000002A2 (en) 2000-12-31
HRP20000002B1 true HRP20000002B1 (en) 2002-06-30

Family

ID=10815370

Family Applications (1)

Application Number Title Priority Date Filing Date
HR970497A HRP20000002B1 (en) 1997-07-04 2000-01-04 Azetidinylpropylpiperidine derivatives, intermediates and use as tachykinin antagonists

Country Status (36)

Country Link
US (1) US6262046B1 (es)
EP (1) EP1023285A1 (es)
JP (1) JP2000511207A (es)
KR (1) KR20010015532A (es)
CN (1) CN1261887A (es)
AP (1) AP1110A (es)
AR (1) AR013171A1 (es)
AU (1) AU726708B2 (es)
BG (1) BG103992A (es)
BR (1) BR9810544A (es)
CA (1) CA2294193A1 (es)
CO (1) CO4950604A1 (es)
DZ (1) DZ2550A1 (es)
EA (1) EA002773B1 (es)
GB (1) GB9714129D0 (es)
GT (1) GT199800106A (es)
HN (1) HN1998003689A (es)
HR (1) HRP20000002B1 (es)
HU (1) HUP0002330A3 (es)
ID (1) ID24090A (es)
IL (1) IL133433A0 (es)
IS (1) IS5295A (es)
MA (1) MA26519A1 (es)
NO (1) NO996115L (es)
NZ (1) NZ501715A (es)
OA (1) OA11236A (es)
PA (1) PA8454601A1 (es)
PE (1) PE83999A1 (es)
PL (1) PL338004A1 (es)
SK (1) SK182799A3 (es)
TN (1) TNSN98127A1 (es)
TR (1) TR200000025T2 (es)
TW (1) TW492960B (es)
UY (1) UY25079A1 (es)
WO (1) WO1999001451A1 (es)
ZA (1) ZA985875B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714129D0 (en) 1997-07-04 1997-09-10 Pfizer Ltd Azetidines
AU1089599A (en) * 1997-10-15 1999-05-03 Coelacanth Chemical Corporation Synthesis of azetidine derivatives
FR2787449B3 (fr) * 1998-12-15 2001-01-12 Sanofi Sa Derives de 3-phenyl-2,6-dioxopiperidin-3-yl propionamide et leur procede de preparation
FR2787448B3 (fr) 1998-12-18 2001-01-12 Sanofi Sa Ester d'alkyle inferieur de l'acide 3-(3,4-dihalogenophenyl) -2,6-dioxopiperidine3-propionique et son mode de preparation
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
US6566356B2 (en) 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
JP4660199B2 (ja) * 2002-12-23 2011-03-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換1−ピペリジン−4−イル−4−アゼチジン−3−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用
TW200508221A (en) 2003-06-13 2005-03-01 Astrazeneca Ab New azetidine compounds
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
FR2876689B1 (fr) * 2004-10-14 2008-02-22 Aventis Pharma Sa Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide
US8604200B2 (en) * 2005-03-08 2013-12-10 Janssen Pharmaceutica N.V. Diaza-spiro-{4,4}-nonane derivatives as neurokinin (NK1) antagonists
US8247442B2 (en) * 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
TW200815353A (en) 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US8106208B2 (en) 2006-05-18 2012-01-31 Albireo Ab Benzamide compounds that act as NK receptor antagonists
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
EP2185540B1 (en) 2007-08-07 2011-07-20 F. Hoffmann-La Roche AG Pyrrolidine aryl-ether as nk3 receptor antagonists
WO2009040659A2 (en) * 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
CN107614504B (zh) 2015-06-23 2019-12-24 卫材R&D管理有限公司 甲酰胺化合物的晶体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625060A (en) 1991-05-03 1997-04-29 Elf Sanofi Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions on which they are present
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
TW432061B (en) 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
FR2729951B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
GB9600235D0 (en) * 1996-01-05 1996-03-06 Pfizer Ltd Therapeutic agents
GB9601697D0 (en) * 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
GB9714129D0 (en) 1997-07-04 1997-09-10 Pfizer Ltd Azetidines

Also Published As

Publication number Publication date
JP2000511207A (ja) 2000-08-29
ID24090A (id) 2000-07-06
PL338004A1 (en) 2000-09-25
EP1023285A1 (en) 2000-08-02
EA199901102A1 (ru) 2000-08-28
US6262046B1 (en) 2001-07-17
WO1999001451A1 (en) 1999-01-14
AR013171A1 (es) 2000-12-13
OA11236A (en) 2003-05-27
CN1261887A (zh) 2000-08-02
UY25079A1 (es) 2000-12-29
AP1110A (en) 2002-10-10
CO4950604A1 (es) 2000-09-01
GT199800106A (es) 2000-01-05
DZ2550A1 (fr) 2003-02-08
TNSN98127A1 (fr) 2005-03-15
HRP20000002A2 (en) 2000-12-31
HUP0002330A2 (hu) 2001-06-28
TW492960B (en) 2002-07-01
MA26519A1 (fr) 2004-12-20
CA2294193A1 (en) 1999-01-14
HUP0002330A3 (en) 2002-05-28
SK182799A3 (en) 2001-11-06
BG103992A (en) 2000-07-31
AP9801291A0 (en) 1998-09-30
NZ501715A (en) 2001-06-29
KR20010015532A (ko) 2001-02-26
AU8806298A (en) 1999-01-25
TR200000025T2 (tr) 2000-06-21
PE83999A1 (es) 1999-09-11
HN1998003689A (es) 1999-01-08
IL133433A0 (en) 2001-04-30
BR9810544A (pt) 2000-09-05
IS5295A (is) 1999-12-10
ZA985875B (en) 2000-01-10
PA8454601A1 (es) 2000-05-24
EA002773B1 (ru) 2002-08-29
GB9714129D0 (en) 1997-09-10
AU726708B2 (en) 2000-11-16
NO996115D0 (no) 1999-12-10
NO996115L (no) 2000-02-22

Similar Documents

Publication Publication Date Title
HUP0002330A3 (en) Azetidinylpropylpiperidine derivatives, intermediates and use as tachykinin antagonists
HUP0101155A3 (en) Imidazonaphthyridines, pharmaceutical compositions thereof and intermediates
HK1030939A1 (en) Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists
SG87776A1 (en) Substituted isoquinoline-3-carboxamides, their preparation and their use as pharmaceuticals
HUP0002869A3 (en) Benzothiophenecarboxamide derivatives, pharmaceutical compositions thereof and intermediates
EP0934305A4 (en) INTEGRINE ANTAGONISTS
EP1007026A4 (en) INTEGRIN ANTAGONISTS
AU5374294A (en) 4-carboxoamido piperidine derivatives, intermediates and use as neurokinin antagonists
HK1078561A1 (en) Novel compounds, their use and preparation
EP0946164A4 (en) INTEGRIN ANTAGONISTS
HUP9903815A3 (en) Substituted purines, pharmaceutical compositions thereof, intermediates
GB9712317D0 (en) Composition, compound and use
NZ324712A (en) 3-azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists
IL134301A0 (en) 2-acylaminopropanamines as tachykinin receptor antagonists
ZA98256B (en) Tachykinin antagonists
IL129660A0 (en) Piperazino derivatives as neurokinin antagonists
GB9705861D0 (en) Trypthophan ureas as neurokinin antagonists
GB9800490D0 (en) Ethane-1 2-diamine derivatives and tachykinin antagonists
HUP9903653A3 (en) Substituted arylalkylamines as neurokinin antagonists
IL134155A0 (en) 2-acylaminopropanamines as tachykinin receptor antagonists
HUP9902563A3 (en) Piperidine derivatives, intermediates, preparation and use thereof
HUP0003622A3 (en) Fungicidal pyrimidin-2-oxy-4-one and pyrimidin-2-oxy-4-thione derivatives, their preparation, intermediates and use
GB9611786D0 (en) Trypthophan ureas as neurokinin antagonists
ZA971467B (en) Piperazino derivatives as neurokinin antagonists.
GB9713264D0 (en) Glucocorticoid antagonists

Legal Events

Date Code Title Description
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
A1OB Publication of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20010701

Year of fee payment: 4

B1PR Patent granted
PBON Lapse due to non-payment of renewal fee

Effective date: 20020702